Short answer
Innoviva, Inc. (INVA) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $98M (up 10.6% year over year) with net income of $187M.
Q1 2026 key financials · XBRL
- Revenue
- $98M
- +10.6% YoY
- Net income
- $187M
- +500.6% YoY
- Operating margin
- 38.9%
- Gross margin
- 77.4%
- EPS (diluted)
- $2.22
- +400.0% YoY
Source: XBRL data from the Innoviva, Inc. (INVA) Q1 2026 10-Q on SEC EDGAR. USD.
Innoviva, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q1 revenue $98.0M, up 11% YoY from $88.6M
- Operating income $38.2M vs $41.4M YoY; net income $186.6M vs $46.6M net loss
- Best product XACDURO sales $18.1M, up 232% YoY; worst XERAVA sales $2.6M, down 30%
- Cash $603.1M; operating cash flow $35.3M vs $48.6M; $20.4M share repurchases
- NUZOLVENCE availability targeted for second half of 2026; cash sufficient for at least 12 months
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 only
- Share-repurchase activity: 971,066 shares bought at average $21.06 during the quarter
- Repurchase authorization: $125.0 million approved November 3, 2025, with $99,973,540 remaining at March 31, 2026
- Convertible debt outstanding: 2.125% Convertible Senior Notes due 2028ેણ
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Innoviva, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.